Infectious Disease

The AJMC® Infectious Disease compendium is a comprehensive resource for news and interviews about the viruses, bacteria, fungi, and parasites that create illness and outbreaks.

Latest News

child getting a vaccination | Image credit: Nina Lawrenson/peopleimages.com - stock.adobe.com
Falling Vaccine Coverage Threatens a Surge in Preventable Diseases

April 24th 2025

World Health Organization headquarters | Image credit: hectorchristiaen - stock.adobe.com
WHO Members Draft Future Pandemic Agreement

April 16th 2025

COVID-19 | Image Credit: © blvdone-stock.adobe.com
Bias Reduction, Better Access Key to COVID-19 Equity Gains

April 14th 2025

Pediatric COVID. | Image Credit: Dmitry Naumov - stock.adobe.com
COVID-19 Linked to Increased Kidney Risks in Children

April 11th 2025

FDA approval graphic | Image Credit: wladimir1804 - stock.adobe.com
FDA Approves First New Class of Oral Antibiotics for Uncomplicated UTIs in Nearly 30 Years

March 25th 2025

The Untold Burden of Uncomplicated UTIs: Addressing Recurrence and Treatment Gaps

Learn about uncomplicated urinary tract infection (UTI) management updates, growing resistance issues, prevention strategies, antimicrobial stewardship, and the socioeconomic impact of treatment failures across diverse patient populations.

Learn about uncomplicated urinary tract infection (UTI) management updates, growing resistance issues, prevention strategies, antimicrobial stewardship, and the socioeconomic impact of treatment failures across diverse patient populations.

More News

Top 5 infectious disease articles.
December 26th 2022

Top 5 Most-Read Infectious Disease Articles of 2022

Matthew Gavidia
The top 5 most-read articles for infectious disease in 2022 explored preventive efforts and therapeutic innovations against Clostridioides difficile infections, as well as federal action on the COVID-19 pandemic.
Jessica Allegretti, MD, MPH.
December 21st 2022

Dr Jessica Allegretti Explains Rebyota’s Mechanism of Action for the Prevention of Recurrent CDI

Matthew Gavidia
Jessica Allegretti, MD, MPH, medical director of the Crohn's and Colitis Center, Brigham and Women's Hospital, explained the mechanism of action for Rebyota, the first fecal transplant therapy approved by the FDA for the prevention of recurrent Clostridioides difficile infection (CDI) in individuals 18 years and older, following antibiotic treatment for recurrent CDI.
Doctors.
December 16th 2022

ICYMI: Top Content From DDW 2022

Matthew Gavidia
Several therapeutic innovations in the management of Clostridioides difficile infection recurrence, current evidence on the efficacy of weight loss procedures in reversing nonalcoholic fatty liver disease, and an interview the use of artificial intelligence were spotlighted at Digestive Disease Week (DDW) 2022.
Doctor and patient.
December 12th 2022

DAA Therapy Linked With Improved Liver, Mortality Outcomes in Patients With Chronic Hepatitis C

Matthew Gavidia
Use of direct-acting antiviral (DAA) treatment (without interferon) was shown to reduce liver and nonliver complications, as well as improve long-term overall survival among patients with chronic hepatitis C.
Hospitalized patient.
December 6th 2022

COVID-19 Mortality Risk More Than Doubled Among Homeless Patients

Matthew Gavidia
A cross-sectional study showed that patients experiencing homelessness were at more than 2-fold greater age-adjusted mortality risk due to COVID-19 compared with the general population, with these increased risks observed across race/ethnicity and sex status.
Hospitalized patient.
December 6th 2022

Glucose-Lowering Drugs May Reduce Risk of COVID-19–Related Adverse Events in Patients With Diabetes

Matthew Gavidia
Patients with diabetes who reported use of sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, or metformin prior to COVID-19 infection were associated with lower COVID-19–related adverse outcomes during hospitalization.
Child vaccine.
December 3rd 2022

Gaps Remain in HPV Vaccine Coverage for Children Due to COVID-19 Pandemic

Matthew Gavidia
The monthly volume of human papillomavirus (HPV) vaccine doses administered have returned to the level observed prior to the COVID-19 pandemic among children in an integrated health care system in California, but HPV vaccine coverage remains lower compared with prepandemic levels.
FDA approved.
December 1st 2022

FDA Approves First Fecal Transplant Therapy for Prevention of CDI Recurrence

Matthew Gavidia
Ferring’s Rebyota, a novel first-in-class microbiota-based live biotherapeutic, has been approved by the FDA for the prevention of recurrence of Clostridioides difficile infection (CDI) in individuals 18 years and older, following antibiotic treatment for recurrent CDI.
Elderly patient.
November 23rd 2022

Nutrition Associated With Recurrent CDI Risk in Elderly Patients

Matthew Gavidia
Elderly Japanese patients with a high geriatric nutritional risk index (GNRI) were associated with significantly better Clostridioides difficile infection (CDI) relapse-free survival compared with those with low GNRI.
vaccine.
November 14th 2022

Examining Predictors of Vaccination Adherence for COVID-19, Influenza

Matthew Gavidia
Individuals who completed their full primary series of COVID-19 vaccination were more likely to report getting the influenza vaccine vs those who did not, and vice versa.
What We're Reading image
November 14th 2022

What We’re Reading: Alzheimer Drug Fails; Impact of Repeated COVID-19 Infection; Psychedelic Compounds Approved

AJMC Staff
Negative trial results come in for Roche’s experimental Alzheimer disease drug; high risks of several adverse outcomes seen with repeated SARS-CoV-2 infection; Colorado has passed a measure to legalize 2 psychedelic compounds for medicinal and recreational use.
Hospitalized child.
November 11th 2022

CDI-Related Mortality Risk Greater in Hospitalized Children With Cystic Fibrosis

Matthew Gavidia
Pediatric patients who developed coexisting Clostridioides difficile infection (CDI) while hospitalized for cystic fibrosis exhibited greater mortality risk, length of stay, and cost compared with those without cooccuring CDI.
patient in hospital bed.
November 8th 2022

Phase 3 Study Shows Live Biotherapeutic Significantly Reduces CDI Recurrence

Matthew Gavidia
A phase 3 study showed Ferring’s RBX2660, an investigational microbiota-based live biotherapeutic, to be safe and significantly reduce recurrence of Clostridioides difficile infection (CDI) after antibiotic treatment, with a sustained response achieved through 6 months.
hospital bed.
November 4th 2022

Substantial Health Care Burden Linked With Recurrent CDI for Medicare Advantage, Commercial Beneficiaries

Matthew Gavidia
A poster presented at the Academy of Managed Care Pharmacy Nexus 2022 showed that patients with recurrent Clostridioides difficile infection (rCDI), who had Medicare Advantage Part D coverage or were enrolled in a commercial health plan were associated with significantly greater health care resource utilization, including emergency department and inpatient visits, compared with those without rCDI.
health care.
November 1st 2022

FDA Rejects Bulevirtide for Hepatitis D, Compensated Liver Disease

Matthew Gavidia
The FDA has issued a complete response letter to Gilead Sciences, indicating that it cannot approve the company’s first-in-class investigational entry-inhibitor, bulevirtide, for the treatment of chronic hepatitis D virus infection and compensated liver disease.
What We're Reading
October 28th 2022

What We’re Reading: Tuberculosis Cases Rise; Racial Disparities in Paxlovid Treatment; Cancer Death Rates Decline

AJMC Staff
The number of tuberculosis cases has risen by 4.5% from 2021; Black and Hispanic patients with COVID-19 were less likely to receive paxlovid in 2022; a new report highlights declines in US cancer death rates between 2015 and 2019.
image of c diff bacteria
October 26th 2022

First-line Fecal Microbiota Transplantation Offers Resolution for Patients With Clostridiodes difficile, Study Says

Pearl Steinzor
Microbiota restoration may be a solution for effectively treating patients with Clostridiodes difficile infection, according to researchers.
Patient in hospital.
October 25th 2022

Updated Clinical Practice Guidelines for CDI Show Improved Outcomes, but Adherence Issues Remain

Matthew Gavidia
Improved outcomes associated with fidaxomicin compared with vancomycin suggest benefits from its greater use in Medicare patients, although uptake remains low despite its recommended use.
Black male patient.
October 20th 2022

Racial Disparities Shown for Influenza Hospitalizations, Vaccination Coverage

Matthew Gavidia
CDC's latest Morbidity and Mortality Weekly Report showed that US adults of non-Hispanic Black, American Indian or Alaska Native, and Hispanic race/ethnicity exhibited significantly higher influenza hospitalization rates and lower vaccination coverage compared with White adults.
physician.
October 18th 2022

Expanded Hepatitis B Vaccination Coverage Associated With Improved Cost Savings, Life Expectancy in Ethiopia

Matthew Gavidia
Compared with Ethiopia’s current nonmandatory hepatitis B vaccination program, expanded vaccination coverage among health care workers was shown to be more cost-effective and result in improved life expectancy gains.
Houses and apartments.
October 13th 2022

Hepatitis C Morbidity, Mortality Risk Reduced in Homeless Patients Through Supportive Housing

Matthew Gavidia
Patients with hepatitis C virus infection and chronic homelessness who were placed into permanent supportive housing exhibited a significantly reduced risk of hospitalization and liver-related morbidity and mortality.
Eye drop.
October 4th 2022

Topical Antibiotics Linked With Reduced Duration of Acute Infective Conjunctivitis in Children

Matthew Gavidia
Children with acute infective conjunctivitis experienced significantly reduced duration of conjunctival symptoms when treated with topical antibiotics.
What We're Reading
October 4th 2022

What We’re Reading: Merger Complete; Monkeypox Vaccine Efficacy Questioned; COVID-19 Travel Advisories Change

AJMC Staff
Optum and Change Healthcare have completed their merger initiated in 2021; efficacy of the Jynneos vaccine is in question after 90 of 7339 individuals contracted monkeypox after vaccination; the CDC will no longer maintain a list of country-by-country COVID-19 travel advisories.
health care.
September 28th 2022

FDA Committee Issues Positive Vote for RBX2660 in Recurrent Clostridioides difficile Infection

Matthew Gavidia
An FDA advisory committee recently issued a positive vote for Ferring’s RBX2660, an investigational microbiota-based live biotherapeutic, for its potential in reducing recurrent Clostridioides difficile infection after antibiotic treatment.
Dialysis.
September 27th 2022

Clostridioides difficile Infection Risk Greater Among Patients Requiring Maintenance Hemodialysis

Matthew Gavidia
Patients requiring maintenance hemodialysis (MHD) had a 4-fold higher risk of Clostridioides difficile infection (CDI), with rates of CDI increasing over time regardless of MHD requirement.
neurologic complications.
September 21st 2022

Headaches, Mood Disturbances Among Neurologic Complications Linked With Monkeypox

Matthew Gavidia
Rare presentations of encephalitis and transverse myelitis are among neurologic consequences linked with orthopoxviruses of smallpox and monkeypox.
What We're Reading
September 16th 2022

What We’re Reading: Flu Season Warnings; Equity in Monkeypox Vaccine; Climate Change and Health Care Services

Julia Bonavitacola
Health experts warn that all should brace for a flu season that could be worse than the past 2 years; the CDC is opening applications to a vaccine equity program that will help those who may have limited access to the monkeypox vaccine; a new report found that health care services will be greatly affected by climate change.
hospital beds
September 13th 2022

Hospital Dramatically Decreased CDI With 2 Interventions

Laura Joszt, MA
Simply adding an admission screening question and a 2-step testing algorithm sharply decreased the number of Clostridioides difficile infections (CDI) in the year after implementing the interventions.
What We're Reading
September 12th 2022

What We’re Reading: Biden Boosts Biotech; 9/11 Program Nearly Depleted; Tpoxx Safe in Monkeypox

AJMC Staff
President Joe Biden is set to sign an order to boost biotech as part of his Cancer Moonshot; the health care program for 9/11 survivors and first responders is running short on money; tecovirimat (Tpoxx) has been found to be safe in patients with monkeypox.
united states.
September 12th 2022

Exploring Current Response and Unmet Needs for Monkeypox: A Q&A With David E. Koren, PharmD, MPH, BCPS, AAHIVP, FIDSA

Matthew Gavidia Hayden E. Klein
David E. Koren, PharmD, MPH, BCPS, AAHIVP, FIDSA, infectious disease clinical pharmacist at Temple University Hospital, provides an update on current preventive efforts to address the monkeypox public health emergency in the United States and what steps are needed to protect at-risk populations.
<1234567891011>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo